Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2011 Scrip 100: Fred Hassan - Challenge 2020

This article was originally published in Scrip

Executive Summary

Ask many in the financial community about life sciences in the next decade, and one hears "it's going to be different, right?" The tone is often sceptical. The investing environment in life sciences has turned unfavourable in recent years. At financial gatherings in New York and elsewhere, one hears how investment funds from sectors such as energy are "in", and how funds representing life sciences are "out". They have a point. The stock indices' – whether it is big pharma or other pharma groupings – show 11 years of no progress, although not unlike the S&P 500.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts